Form 4: Neurogene Director Sarah Noonberg Granted 12,050 Stock Options

Neurogene Inc. Director Sarah B. Noonberg was granted 12,050 non-qualified stock options with an exercise price of $20.40, vesting monthly over one year.

Summary

• Sarah B. Noonberg, a Director of Neurogene Inc. (NGNE), was granted 12,050 non-qualified stock options.
• The options have an exercise price of $20.40 per share.
• The transaction date for this grant was June 12, 2025.
• The options will vest as to 1/12 of the total shares monthly, commencing July 12, 2025, and will be fully vested by June 12, 2026.
• Vesting is contingent upon Ms. Noonberg's continued provision of service to Neurogene Inc. on each vesting date.
• The expiration date for these options is June 12, 2035.
• Following this transaction, Ms. Noonberg beneficially owns 12,050 derivative securities (non-qualified stock options).
• The filing was executed by Donna M. Cochener, acting as attorney-in-fact for Sarah B. Noonberg, under a Power of Attorney dated June 12, 2025, which authorizes the filing of SEC Forms 3, 4, and 5.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event (expected), which is positive for the recipient and aligns interests, but does not indicate any significant new positive or negative developments for the company's operations or financials.

Positives

• The grant of stock options aligns the interests of Director Sarah B. Noonberg with those of the shareholders, as the value of the options is tied to the company's stock performance.
• This is a standard form of compensation for directors, indicating continued engagement and commitment from key personnel.

Risks

• The value of the granted options is subject to market fluctuations of Neurogene Inc.'s common stock; if the stock price does not exceed the exercise price of $20.40, the options may expire worthless.
• Potential future dilution for existing shareholders if the options are exercised, increasing the number of outstanding shares.

Future Outlook

The document primarily details a past transaction (option grant) and its future vesting schedule. It does not provide forward-looking statements regarding the company's financial performance or strategic direction, beyond the terms of the option grant itself.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain talent, and to align the interests of management and directors with those of shareholders. This filing is a routine disclosure of such compensation.

Corporate Governance

Related Party Transactions

• The grant of non-qualified stock options to Sarah B. Noonberg, a director of Neurogene Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned interests between the director and company performance.
• Employees: No direct impact on general employees from this specific filing.

Next Steps

• The options will begin vesting monthly starting July 12, 2025, subject to the director's continued service.
• The options will be fully vested by June 12, 2026.

Key Dates

Keywords

Neurogene Inc., NGNE, Form 4, Stock Option Grant, Director Compensation, Insider Transaction, Non-Qualified Stock Option, Equity Compensation, SEC Filing